Side-by-side · Research reference

DermorphinvsGHRP-6

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED20/47 cited

BPhase 1HUMAN-REVIEWED10/36 cited

Dermorphin

Opioid Peptide · μ-Receptor Agonist · Research Only

~30×Morphine potency

μ-selectiveReceptor typeNegri 1992

D-Ala²Unique featureAmiche 1998

Research only · ICV / SC (animal models)

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Dermorphin

GHRP-6

Primary target

μ-opioid receptors (central and peripheral)Negri 1992 Steel 2014

Ghrelin receptor (GHS-R1a)Bowers 1990

Pathway

μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

Downstream effect

Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Feedback intact?

N/A — exogenous opioid agonist

—

Origin

Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998 Mignogna 1992

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Antibody development

Site-directed antibodies produced for detection and purificationCucumel 1996

—

02Dosage Protocols

Parameter

Dermorphin

GHRP-6

Legal status

Controlled substance in many jurisdictions · Research only

Not approved for human use.

—

Animal research (ICV)

Low nanomolar to picomolar range

Intracerebroventricular administration in rodent models.

—

Detection limit (doping)

5 pg/mL in equine plasma/urineSteel 2014

High-throughput LC-MS/MS screen developed for racing industry.

—

Duration of action

10–120 minutes (dose-dependent, intrathecal)

—

Evidence basis

Animal studies · In vitro assays

Phase 1 + clinical practiceBowers 1990

Human toxicity

Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025

—

Standard dose

—

100–200 mcg per injectionBowers 1990

Frequency

—

1–3× per day

Lower / starter dose

—

50 mcg per dose

Duration

—

8–12 weeks on / 4 off

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-meal preferred for appetite support

Half-life

—

~15 minMalagón 1999

04Side Effects & Safety

Parameter

Dermorphin

GHRP-6

Opioid effects

Respiratory depression, sedation, euphoria, tolerance, dependence risk

—

CNS effects

Analgesia (high-affinity sites), catalepsy (low-affinity sites)Negri 1992

—

Kambô ritual toxicity

Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025

—

Peripheral effects

GI motility inhibition (ileum > vas deferens in vitro)Negri 1992

—

Receptor selectivity caveat

Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992

—

Proteolytic stability

Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996

—

Hunger

—

Pronounced — defining feature vs ipamorelin

Cortisol elevation

—

Mild

Prolactin elevation

—

Mild

Injection site reaction

—

Mild

Cancer risk

—

Contraindicated in active malignancy

Pregnancy / OB

—

Avoid

Absolute Contraindications

Dermorphin

·Human use — not approved by any regulatory authority
·Controlled substance status — possession illegal in many jurisdictions
·Known opioid hypersensitivity or respiratory compromise

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

Relative Contraindications

Dermorphin

·Any context outside approved animal research protocols
·CNS depressant co-administration

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

05Administration Protocol

Parameter

Dermorphin

GHRP-6

1. Legal and ethical framework

Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

2. Animal research protocols

In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.

SQ — abdomen. Rotate sites.

3. Analytical detection

High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014

Pre-meal for appetite support; pre-sleep for GH alignment.

4. Kambô ritual (traditional use)

Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.